Table 1.
Number of participants screened, enrolled, and finishing follow-up and characteristics at baseline as part of therapeutic efficacy monitoring in Angola, 2015
| Benguela | Zaire | Lunda Sul | ||||
|---|---|---|---|---|---|---|
| ASAQa | ALa | ALa | DPb | DPb | ASAQa | |
| Screened, n | 445 | 443 | 150 | 223 | 318 | 225 |
| Enrolled, n | 101 | 101 | 104 | 102 | 100 | 78 |
| Lost to follow up, n (%) | 20 (20) | 11 (11) | 7 (7) | 12 (12) | 14 (14) | 9 (12) |
| Excluded, n (%) | 8 (8) | 5 (5) | 4 (4) | 6 (6) | 10 (10) | 13 (17) |
| Reached study endpoint, n (%) | 73 (72) | 85 (84) | 93 (89) | 84 (82) | 76 (76) | 56 (72) |
| Participant characteristics at baseline | ||||||
| Median age, years (range) | 5.0 (0.7–12) | 6.4 (1–12) | 3.0 (0.6–5) | 2.8 (0.6–5) | 2.8 (0.5–5) | 3.2 (0.5–5) |
| Median weight, kg (range) | 16 (6–37) | 18 (8–42) | 13 (7–19) | 13 (6–19) | 12 (6–21) | 12 (7–18) |
| Percent female | 40% | 40% | 51% | 53% | 42% | 58% |
| Median day 0 parasitemia, parasites/µL (range) | 29,487 (1051–99,507) | 20,151 (1003–92,733) | 47,766 (2034–195,529) | 48,049 (2003–187,777) | 7266 (2000–180,903) | 16,071 (2000–161,333) |
| Median day 0 hemoglobin, g/dL (range) | 10.3 (5.2–13.3) | 10.2 (5.4–13.5) | 10.2 (5.7–13.6) | 10.0 (6–13.3) | 9.4 (5.1–13.5) | 9.2 (5.5–13.6) |
ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
a28-day follow-up
b42-day follow-up